`
`D An official EU website
`
`Macugen I European Medicines Agency
`
`~ EUROPEAN MEDICINES AGENCY
`
`\ ; ; ; , SCIENCE MEDICINES HEALTH
`
`Macugen
`
`pegaptanib
`
`Table of contents
`
`• Overview
`• Authorisation details
`• Product information
`• Assessment history
`
`WITHDRAWN
`This medicine is now withdrawn from use in the European Union.
`
`Overview
`
`The marketing authorisation for Macugen has been withdrawn at the request of the marketing(cid:173)
`authorisation holder.
`
`~ Macugen : EPAR - Summary for the public (PDF/520.99 KB)
`
`First published: 31/05/2007
`Last updated: 27/06/2019
`
`More detail is available in the summary of product characteristics
`
`This EPAR was last updated on 27/06/2019
`
`Authorisation details
`
`Name
`
`Macugen
`
`Available languages (21)
`
`v
`
`https://www.ema.europa.eu/en/medicines/human/EPAR/macugen
`
`1/5
`
`Novartis Exhibit 2279.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`=89:6JÿKLMN76Oÿ:7PQ9L
`
`
`ÿ ÿ
` ÿÿ
`<4<=/>/?/...2-.
`=6ORS9ÿT7QTO5:69
`K985KO5:RQ
`@:O9L:5ORM:5Uÿ:M:;KLMKLR9O5LJÿ:5P9ÿV@WWXÿMLÿ6MPPM:ÿ:5P9
`K985KO5:RQ
`YZ9L5K97OR6ÿ5L95ÿV49[>X
`\9Oÿ4567U5Lÿ]989:9L5ORM:
`=:5OMPR65UÿOZ9L5K97OR6ÿ6Z9PR65UÿV=Y?Xÿ6MN9
`[.1^=._
`45L`9OR:8;57OZMLRT5ORM:ÿZMUN9L
`aZ5LP5[bRTTÿ?9T`5ÿc9K7QUR`5ÿTdLdM
`c9SRTRM:
`1B]5O9ÿMeÿRTT79ÿMeÿP5L`9OR:8ÿ57OZMLRT5ORM:ÿS5URNÿOZLM78ZM7OÿOZ9ÿ<7LMK95:ÿf:RM:
`_1/.1/-..2
`?M:O56Oÿ5NNL9TT
`g5:`MS6MS5ÿ1B2h/-6ÿ
`^R8ZOZM7T9ÿ
`10...ÿaL5879ÿ0ÿ
`?i96Zÿc9K7QUR6
`
` !"#$%&ÿ()*"!+,&(")
`-./.0/-.12ÿ456789:ÿ;ÿ<4<=/>/?/...2-.ÿ;ÿ@A/..2B
`456789:ÿjÿ<a=cÿ;ÿaLMN76Oÿ@:eMLP5ORM:ÿVa]k/l_-dB_ÿmAX
`ÿkRLTOÿK7QURTZ9Njÿ._/.l/-..hÿ
`^5TOÿ7KN5O9Njÿ-0/.2/-.1h
`C
`D
`EDÿD
`
` ÿFGHÿI
`
`
`
`
`
`
`
`
`Novartis Exhibit 2279.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`•
`•
`•
`•
`•
`
` !"#$"#%&''()ÿ+ÿ,ÿ-.//012ÿ34ÿ5136.78ÿ7901078(1:;8:7;
`
`
`ÿ ÿ
` ÿÿ
`&''()ÿ++&ÿ,ÿ<0'.4078.1:'=,0.8931:;08:3'ÿ93>6(1ÿ1(;53';:?>(ÿ431ÿ?0879ÿ1(>(0;(
`&''()ÿ++@ÿ,ÿA3'6:8:3';ÿ34ÿ89(ÿ/01B(8:'=ÿ0.8931:;08:3'
`&''()ÿ+++&ÿ,ÿC0?(>>:'=
`&''()ÿ+++@ÿ,ÿD07B0=(ÿ>(04>(8
`D>(0;(ÿ'38(ÿ8908ÿ89(ÿ;:E(ÿ34ÿ89(ÿ0?3F(ÿ637./('8ÿ70'ÿ()7((6ÿGHÿ50=(;I
`J3.ÿ01(ÿ89(1(431(ÿ06F:;(6ÿ83ÿ?(ÿ;(>(78:F(ÿ0?3.8ÿK9:79ÿ;(78:3';ÿ31ÿ50=(;ÿ23.ÿK:;9ÿ83ÿ51:'8I
`<07.=('ÿgÿhD&iÿ,ÿ&>>ÿ&.8931:;(6ÿ51(;('808:3';ÿ`DbjklGmInoÿp@a
`ÿj:1;8ÿ5.?>:;9(6gÿHGkHqkqHHrÿ
`C0;8ÿ.5608(6gÿqmkHokqHsn
`L
`M
`NMÿM
`
` ÿO PÿQ
`<07.=('ÿgÿhD&iÿ,ÿA3'6:8:3';ÿ:/53;(6ÿ3'ÿ/(/?(1ÿ;808(;ÿ431ÿ;04(ÿ0'6ÿ(44(78:F(ÿ.;(ÿ,
`&''()ÿ+tÿ`DbjklmmIumÿp@a
`ÿj:1;8ÿ5.?>:;9(6gÿsukHmkqHHmÿ
`C0;8ÿ.5608(6gÿqmkHokqHsn
`L
`M
`NMÿM
`
` ÿO PÿQ
`RSTUVTW!#S$UTX$Y#ZWÿ\U!YX
`]59890>/3>3=:70>;
`^S$UTX$Y#ZWÿZ"_ZWT#Z!"
`<07.=('ÿ:;ÿ:'6:708(6ÿ431ÿ89(ÿ81(08/('8ÿ34ÿ'(3F0;7.>01ÿ`K(8aÿ0=(,1(>08(6ÿ/07.>01ÿ6(=('(108:3'
``&<baIc%%$%%V$"#ÿSZ%#!Ud
` ST"\$%ÿ%Z"W$ÿZ"Z#ZTeÿTY#S!UZ%T#Z!"ÿ!fÿV$_ZWZ"$
`<07.=('ÿgÿhD&iÿ,ÿD137(6.10>ÿ;8(5;ÿ80B('ÿ0'6ÿ;7:('8:4:7ÿ:'431/08:3'ÿ048(1ÿ0.8931:;08:3'
``DbjkorrInqÿp@a
`
`
`
`
`
`
`
`
`Novartis Exhibit 2279.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`
`
`ÿ ÿ
` ÿÿ
`ÿMAELBÿG:NHALC<D>ÿOPQORQSOOTÿ
`U8LBÿ:GD8B<D>ÿSVQOWQSOXT
`!"#$#%&ÿ(%)*+$#",-%.$/0)#1%$#0"ÿ203.(+"$1
`789:;<=ÿ>ÿYJZ[ÿ\ÿJEI9<D:E8HÿLB<GLÿB8]<=ÿN<^IE<ÿ8:BCIEAL8BAI=ÿ_J`MQaRSbTSÿcde
`ÿMAELBÿG:NHALC<D>ÿPXQOfQSOOVÿ
`U8LBÿ:GD8B<D>ÿSVQOWQSOXT
`789:;<=ÿ>ÿYJZ[ÿ\ÿg9A<=BA^A9ÿ`AL9:LLAI=ÿ_J`MQTRabXXÿcde
`ÿMAELBÿG:NHALC<D>ÿPXQOfQSOOVÿ
`U8LBÿ:GD8B<D>ÿSVQOWQSOXT
`40)+ÿ#"50)(%$#0"ÿ0"ÿ4%3.,+"
`6+&%$+2ÿ30"$+"$
`789:;<=>ÿ@ABCDE8F=ÿ8GGHA98BAI=
`789:;<=>ÿJ8<DA8BEA9ÿA=K<LBA;8BAI=ÿGH8=
`hijklhk
`Y:EIG<8=ÿ7<DA9A=<LÿZ;<=9mÿ
``In<=A9Iÿg98EH8BBAH88=ÿWÿ
`XORPÿogÿZnLB<ED8nÿ
`pC<ÿq<BC<EH8=DL
`p<H>ÿrPXÿ_OeRRÿVRXÿWOOO
`oIFÿBIÿ^A=Dÿ:L
`JILB8Hÿ8DDE<LLÿ8=DÿD<HAK<EA<L
`d:LA=<LLÿCI:ELÿ8=DÿCIHAD8mL
`MIEÿBC<ÿs=AB<DÿcA=;DIntÿ8LÿI^ÿXÿu8=:8EmÿSOSXtÿY:EIG<8=ÿs=AI=ÿH8Fÿ8GGHA<LÿI=HmÿBIÿBC<ÿB<EEABIEmÿI^ÿqIEBC<E=
`vE<H8=Dÿ_qveÿBIÿBC<ÿ<wB<=Bÿ^IE<L<<=ÿA=ÿBC<ÿJEIBI9IHÿI=ÿvE<H8=DÿQÿqvb
`xÿXTTf\SOSSÿY:EIG<8=ÿ7<DA9A=<LÿZ;<=9m
`Y:EIG<8=ÿs=AI=ÿ8;<=9A<Lÿ=<BFIE]
`
`
`
`
`
`
`•
`•
`
`/ '
`
`
`
`
`
`Novartis Exhibit 2279.004
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`1/11/22, 2:35 PM
`
` ÿÿ
`
`Macugen| European Medicines Agency
`
`
`
`ÿ ÿ
` !ÿ#$%!&'ÿ()ÿ*+%ÿ,-.(/%#!ÿ0!1(!-
`
`An agency of the European Union [BS]
`
`https:/Awww.ema.europa.eu/en/medicines/human/EPAR/macugen
`
`
`
`
`
`
`
`Novartis Exhibit 2279.005
`Regeneron v. Novartis, IPR202 1-008 16
`
`5/5
`
`
`
`Novartis Exhibit 2279.005
`Regeneron v. Novartis, IPR2021-00816
`
`